Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas
Oncotarget2016Vol. 7(16), pp. 21763–21774
Citations Over TimeTop 10% of 2016 papers
Doris Helbig, Michaela A. Ihle, Katharina Pütz, Iliana Tantcheva‐Poór, Cornelia Mauch, Reinhard Büttner, Alexander Quaas
Abstract
UV-induced TP53 mutations as well as CCND1/CDK4 changes seem to play essential roles in tumorigenesis of PDS. Furthermore, we found some more interesting mutated genes in other oncogene pathways (activating mutations of HRAS and PIK3CA). All AFX and PDS investigated immunohistochemically presented with similar oncogene expression profiles (TP53, CCND1, CDK4 overexpression) and the single case with an AFX and PDS showed complete identical TP53 and PIK3CA mutation profiles in both tumors. This reinforces our hypothesis that AFX is the non-infiltrating precursor lesion of PDS.
Related Papers
- → Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas(2004)160 cited
- → Drugging All RAS Isoforms With One Pocket(2020)73 cited
- → Frequency of RAS Mutations (KRAS, NRAS, HRAS) in Human Solid Cancer(2017)51 cited
- → Ras Mutations in Cancer(2013)4 cited
- → The landscape of RAS mutations and hotspots in Chinese patients with solid tumors.(2022)